Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of ZK 230211 doses in second-line endocrine therapy for metastatic breast cancer
2005-005581-36Phase 2Terminated
- Sponsor
- Schering AG
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lonaprisan in breast cancer (2 arms), sponsored by Schering AG. Primary endpoint: Clinical Benefit (CB). Started May 2006; status: terminated.
02
Drugs
lonaprisan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005581-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005581-36.